<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2011234513
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2023
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Lertiv
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        LERCANIDIPINE HYDROCHLORIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        41.40
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Hetero Labs Limited Unit &#x2013; V" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Hetero Labs Limited Unit – V
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2950]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Saudi Amarox
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Saudi Amarox
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        QC08CA13
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Lertiv, Lercanidipine hydrochloride, belongs to a group of medicines called Calcium Channel Blockers (dihydropyridine derivatives) that lower blood pressure.</p><p>Lertiv is used to treat high blood pressure also known as hypertension in adults over the age of 18 years (it is not recommended for children under 18 years old).</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Lertiv</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are allergic to Lercanidipine hydrochloride or any of the other ingredients of this medicine</p><p>(Listed in section 6).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are suffering from certain heart diseases:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Obstruction to flow of blood from the heart</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Untreated heart failure</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Unstable angina (chest discomfort occurring at rest or progressively increasing)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Within one month of heart attack.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have severe liver problems.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have severe kidney problems or you are undergoing dialysis.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are taking medicines that are inhibitors of the hepatic metabolism, such as:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; antifungal medicines (such as ketoconazole or itraconazole)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; macrolide antibiotics (such as erythromycin. troleandomycin or clarithromycin)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; antivirals (such as ritonavir).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are taking another medicine called ciclosporin or cyclosporin (used after transplants</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to prevent organ rejection).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; With grapefruit or grapefruit juice.</p><p><strong>Warning and precautions </strong></p><p>Talk to your doctor or pharmacist before taking Lertiv:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have a heart problem</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have liver or kidney problems</p><p>You must tell your doctor if you think you are (or might become) pregnant or breast-feeding (see pregnancy, breast-feeding and fertility section).<br /><strong>Children and adolescents. </strong></p><p>The safety and efficacy of Lertiv in children aged up to 18 years have not been established.</p><p><strong>Other medicines and Lertiv </strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. This is because when Lertiv is taken with other medicines the effect of Lertiv or of the other medicine may be changed or certain side effects may occur more frequently (see also section 2 &ldquo;Do not take Lertiv&rdquo;).</p><p>In particular, tell your doctor or pharmacist if you are taking any of the following medicines:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; phenytoin, phenobarbital or carbamazepine (medicines for epilepsy)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rifampicin (a medicine to treat tuberculosis)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; astemizole or terfenadine (medicines for allergies)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; amiodarone, quinidine or sotalol (medicines to treat a fast heart beat)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; midazolam (a medicine that helps you sleep)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; digoxin (a medicine to treat a heart problem)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; beta-blockers e.g. metoprolol (a medicine to treat high blood pressure, heart failure and abnormalheart rhythm)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cimetidine (more than 800 mg, a medicine for ulcers, indigestion, or heartburn)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; simvastatin (a medicine to lower cholesterol in your blood)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; other medicines to treat high blood pressure</p><p>Lertiv with food, drink and alcohol</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A high fat meal significantly increases blood levels of the medicine (see section 3).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Alcohol can increase the effect of Lertiv. Do not consume alcohol during treatment with Lertiv.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lertiv must not be taken with grapefruit or grapefruit juice (they can increase its hypotensive effect). See section 2 &ldquo;Do not take Lertiv&rdquo;.</p><p><strong>Pregnancy, breast-feeding and fertility </strong></p><p>Lertiv is not recommended if you are pregnant, it should not be used during breast-feeding. There are no data from the use of Lertiv in pregnant women and in nursing mothers. If you are pregnant or breast-feeding, if you are not using any contraceptive method, you think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p><strong>Driving and using machines </strong></p><p>If you develop dizziness, weakness or drowsiness with this medicine, do not drive a vehicle or operate machines.</p><p><strong>Lertiv contains lactose </strong></p><p>If you have been told by your doctor that you have an intolerance to some sugars, contact your</p><p>Doctor before taking this medicinal product.</p><p><strong>Sodium </strong></p><p>This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially</p><p>&ldquo;Sodium-free&rdquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or</p><p>Pharmacist if you are not sure.</p><p><strong>Adults:</strong> the recommended dose is 10 mg once daily at the same time each day, preferably in the morning at least 15 minutes before breakfast. Your doctor may advise you to increase the dose to one Lertiv 20 mg daily, if needed. (see section 2 &ldquo;Lertiv with food, drink and alcohol&rdquo;).</p><p>Lertiv 10 mg: the score line is only to facilitate breaking for ease of swallowing and not to divide into equal doses.</p><p>Lertiv 20 mg: the tablet can be divided into equal doses.</p><p>The tablets should preferably be swallowed whole with some water.</p><p><strong>Use in children:</strong> This medicine should not be used in children under 18 years of age.</p><p>Elderly patients: No adjustment of the daily dose is required. However, special care should be exercised in starting treatment.</p><p>Patients with liver or kidney problems: special care is needed in starting treatment in these patients and an increase in daily dose to 20 mg should be approached with caution.</p><p><strong>If you take more Lertiv than you should </strong></p><p>Do not exceed the prescribed dose. If you have taken more than the prescribed dose, talk to your doctor or go to the hospital straight away. Take the medicine pack with you. Taking more than the correct dose can cause an excessive drop in blood pressure and your heart can beat irregularly or faster.</p><p><strong>If you forget to take Lertiv </strong></p><p>If you forget to take your tablet simply miss that dose and then go on as before. Do not take a double dose to make up for a forgotten dose.</p><p><strong>If you stop taking Lertiv </strong></p><p>If you stop taking Lertiv your blood pressure may increase again. Please consult your doctor before stopping the treatment.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. The following side effects may happen with this medicine:</p><p>Some side effects can be serious.</p><p>If any of the following happen, tell your doctor straight away:</p><p>Rare (may affect up to 1 in 1,000 people): angina pectoris (e.g. chest tightness due to lack of blood to your heart), allergic reactions (symptoms include itching, rash, urticaria), fainting.</p><p>Patients with pre-existing angina pectoris may experience increased frequency, duration or severity</p><p>of these attacks with the group of medicines to which Lertiv belongs. Isolated cases of heart attack may be observed.</p><p>Other possible side effects:</p><p>Common (may affect up to 1 in 10 people): headache, fast heart rate, feeling of fast or uneven heart beat (palpitations), sudden reddening of your face, neck or upper chest (flushing), ankle swelling. Uncommon (may affect up to 1 in 100 people): dizziness, fall in blood pressure, heartburn, feeling sick, stomach pain, skin rash, itching, muscle pain, passage of large amounts of urine, feeling weak or feeling tired.</p><p>Rare (may affect up to 1 in 1,000 people): sleepiness, vomiting, diarrhoea, hives, increase in the usual number of times one urinates, chest pain.</p><p>Not known (frequency cannot be estimated from the available data): swelling of gums, changes in liver function (detected by blood tests), cloudy fluid (when performing dialysis through a tube into your abdomen), swelling of your face, lip, tongue or throat which may cause difficulty in breathing or swallowing.</p><p>Reporting of suspected adverse reactions</p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions. &nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>To report any side effect(s):</strong></p><p>&bull;&nbsp; <strong>Saudi Arabia:</strong></p><table border="1" cellspacing="0" cellpadding="0" align="left"><tbody><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call Center: 19999</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; o Website: https://ade.sfda.gov.sa/</p></td></tr></tbody></table><p><strong><em>&nbsp;</em></strong></p><p><strong><em>&nbsp;</em></strong></p><p><strong><em>&nbsp;</em></strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>&bull;&nbsp; <strong>Other GCC States:</strong></p><p><!--[if gte vml 1]><v:shapetype id="_x0000_t202"
 coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="Text_x0020_Box_x0020_2" o:spid="_x0000_s1026"
 type="#_x0000_t202" style='position:absolute;margin-left:5.3pt;margin-top:6.35pt;
 width:456.4pt;height:18.75pt;z-index:251659264;visibility:visible;
 mso-wrap-style:square;mso-width-percent:0;mso-height-percent:0;
 mso-wrap-distance-left:9pt;mso-wrap-distance-top:3.6pt;
 mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:3.6pt;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:margin;
 mso-position-vertical:absolute;mso-position-vertical-relative:text;
 mso-width-percent:0;mso-height-percent:0;mso-width-relative:margin;
 mso-height-relative:margin;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
 <v:textbox>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoListParagraph style='margin-top:0in;margin-right:0in;
    margin-bottom:0in;margin-left:.25in;text-align:justify;text-justify:inter-ideograph;
    text-indent:-.25in;line-height:150%;mso-pagination:none;mso-list:l0 level1 lfo4;
    text-autospace:none'><![if !supportLists]><span lang=EN-IN
    style='mso-bidi-font-size:12.0pt;line-height:150%;mso-ansi-language:EN-IN'><span
    style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=LTR></span><span lang=EN-IN
    style='mso-bidi-font-size:12.0pt;line-height:150%;mso-ansi-language:EN-IN'>Please
    contact the relevant competent authority.<o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap type="square" anchorx="margin"/>
</v:shape><![endif]--><img width="613" height="29" alt="Text Box: -	Please contact the relevant competent authority." src="file:///C:/Users/Lenovo/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /></p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&nbsp;</p><p>&bull;&nbsp;&nbsp; Store below 30&deg;C.</p><p>&bull;&nbsp;&nbsp; Keep out of reach of children.</p><p>&bull;&nbsp;&nbsp; Do not use this medicine after the expiry date which is stated on the pack after EXP. The expiry date refers to the last day of the month.</p><p>&bull;&nbsp;&nbsp; Do not throw away any medicines via wastewater or household waste. Ask your pharmacist howto throw away medicines you no longer use. These measures will help protect the environment.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Lertiv contains </strong></p><p>The active substance is Lercanidipine hydrochloride Hemihydrate.</p><p><strong>Lercanidipine Hydrochloride Film-Coated Tablets 10mg </strong><sup>&nbsp;</sup></p><p>Each film coated tablet contains: Lercanidipine Hydrochloride (as Hemihydrate) 10mg.</p><p>&nbsp; The other ingredients are: Lactose monohydrate; Cellulose, Microcrystalline, Sodium starch glycolate,</p><p>Type -A (Primojel) (Part-&nbsp; I}; Povidone, Cellulose, Microcrystalline, Sodium starch glycolate, Type -</p><p>A,(Primojel) (Part-II) Magnesium stearate. <strong>&nbsp;&nbsp;Film coating composition:&nbsp; </strong></p><p>&nbsp; Polyvinyl alcohol-part Hydrolyzed; Titanium Dioxide ; Macrogol/Peg; Talc;Iron Oxide Yellow</p><p>&nbsp; Iron Oxide.</p><p>&nbsp; <strong>Lercanidipine Hydrochloride Film-Coated Tablets 20mg:&nbsp; </strong></p><p>Each film coated tablet contains: Lercanidipine Hydrochloride (as Hemihydrate) 20mg.</p><p>&nbsp; The other ingredients are: Lactose monohydrate; Cellulose, Microcrystalline, Sodium starch glycolate, Type -A (Primojel) (Part- I}; Povidone, Cellulose, Microcrystalline, Sodium starch glycolate, Type -A,</p><p>(Primojel) (Part-II) Magnesium stearate. <strong>&nbsp;&nbsp;Film coating composition:&nbsp; </strong></p><p>&nbsp; Polyvinyl alcohol-part Hydrolyzed; Titanium Dioxide; Macrogol/Peg; Talc; Iron Oxide Red. <strong>&nbsp;&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                What Lercanidipine Hydrochloride looks like?  
  Lercanidipine Hydrochloride Film-Coated Tablets 10mg: 
  Yellow, film coated, round shaped, biconvex tablets debossed with '3' and '4' on either side of score line on one side of tablet and "HL" on the other side. 
 Lercanidipine Hydrochloride Film-Coated Tablets 20mg: 
 Pink to peach, film coated, round shaped, biconvex tablets debossed with '3' and '5' on either side of score line on one side of tablet and "HL" on the other side. 
How supplied: 
Lertiv is supplied in 10's White opaque PVC/Aclar-Alu Blister pack. 
Lertiv 10 – 30’s and 60’s pack 
Lertiv 20 – 30’s and 60’s pack 


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder and Manufacturer </strong></p><p><strong>Saudi Amarox Industrial Company </strong><sub>&nbsp;</sub></p><p>Aljameah Street, Malaz quarter,&nbsp;</p><p>Riyadh 12629, Saudi Arabia<br />Tel: +966 11 22608850<br /><strong>Manufacturer:</strong><br />Hetero Labs Limited Unit V, India</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Last revised in December 2023, Version 1
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">ينتمي لرتيف إلى مجموعة من الأدوية تسمى حاصرات قنوات الكالسيوم (مشتقات ديهيدروبيريدين) التي تخفض ضغط الدم.</p><p dir="RTL">يستخدم لرتيف لعلاج ارتفاع ضغط الدم المعروف أيضًا باسم ارتفاع ضغط الدم لدى البالغين الذين تزيد أعمارهم عن 18 عامًا (لا ينصح به للأطفال دون سن 18 عامًا).</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>&nbsp;</strong><strong>لا تستخدم لرتيف أقراص</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حساسية تجاه ليركانيديبين هيدروكلوريد أو أي من المكونات الأخرى لهذا الدواء (المدرجة في القسم 6).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من بعض أمراض القلب:</p><p dir="RTL">إعاقة تدفق الدم من القلب</p><p dir="RTL">قصور القلب غير المعالج</p><p dir="RTL">الذبحة الصدرية غير المستقرة (ألم الصدر يحدث أثناء الراحة أو يزداد تدريجياً) خلال شهر من الإصابة بنوبة قلبية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشاكل خطيرة في الكبد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشاكل خطيرة في الكلى أو إذا كنت تخضع لغسيل الكلى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول أدوية مثبطات التمثيل الغذائي للكبد ، مثل:</p><p dir="RTL">الأدوية المضادة للفطريات (مثل كيتوكونازول أو إيتراكونازول)</p><p dir="RTL">المضادات الحيوية ماكرولايد (مثل الإريثروميسين. ترولياندوميسين أو كلاريثروميسين)</p><p dir="RTL">مضادات الفيروسات (مثل ريتونافير).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول دواء آخر يسمى سيكلوسبورين أو سيكلوسبورين (يستخدم بعد عمليات الزرع لمنع رفض العضو).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مع الجريب فروت أو عصير الجريب فروت.</p><p dir="RTL"><strong>التحذيرات والاحتياطات</strong></p><p dir="RTL">تحدث إلى طبيبك أو الصيدلي قبل تناول لرتيف:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك مشكلة في القلب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشاكل في الكبد أو الكلى</p><p dir="RTL">يجب عليك إخبار طبيبك إذا كنت تعتقدين أنك (أو قد تصبحين) حاملاً أو مرضعة (انظر قسم الحمل والرضاعة والخصوبة).</p><p dir="RTL"><strong>الأطفال والمراهقين</strong></p><p dir="RTL">لم تثبت سلامة وفعالية لرتيف في الأطفال حتى سن 18 عامًا.</p><p dir="RTL"><strong>الأدوية الأخرى و لرتيف أقراص</strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أي أدوية أخرى. هذا لأنه عندما يتم تناول لرتيف مع أدوية أخرى ، قد يتغير تأثير لرتيف أو الدواء الآخر أو قد تحدث آثار جانبية معينة بشكل متكرر (انظر أيضًا القسم 2 &quot;لا تتناول لرتيف &quot;).</p><p dir="RTL">على وجه الخصوص ، أخبر طبيبك أو الصيدلي إذا كنت تتناول أيًا من الأدوية التالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الفينيتوين أو الفينوباربيتال أو الكاربامازيبين (أدوية الصرع)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ريفامبيسين (دواء لعلاج السل)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أستيميزول أو تيرفينادين (أدوية الحساسية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أميودارون أو كينيدين أو سوتالول (أدوية لعلاج ضربات القلب السريعة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الميدازولام (دواء يساعدك على النوم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الديجوكسين (دواء لعلاج مشكلة في القلب)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حاصرات بيتا ، على سبيل المثال ميتوبرولول (دواء لعلاج ارتفاع ضغط الدم وفشل القلب واضطراب نظم القلب)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيميتيدين (أكثر من 800 ملجرام ، دواء للقرحة ، عسر الهضم ، أو حرقة المعدة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيمفاستاتين (دواء لخفض نسبة الكوليسترول في الدم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية أخرى لعلاج ارتفاع ضغط الدم مع الطعام والشراب والكحول</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الوجبة الغنية بالدهون تزيد بشكل كبير من مستويات الدواء في الدم (انظر القسم 3).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الكحول يمكن أن يزيد من تأثير لرتيف. لا تستهلك الكحول أثناء العلاج باستخدام لرتيف.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا ينبغي أن يؤخذ لرتيف مع الجريب فروت أو عصير الجريب فروت (يمكن أن يزيد من تأثيره الخافض لضغط الدم). انظر القسم 2 &quot;لا تتناول لرتيف&quot;.</p><p dir="RTL"><strong>الحمل والرضاعة</strong></p><p dir="RTL">لا ينصح باستخدام لرتيف إذا كنت حاملاً ، ولا يجب استخدامه أثناء الرضاعة. لا توجد بيانات عن سلامة استخدام لرتيف في النساء الحوامل والمرضعات. إذا كنت حاملا أو مرضعة ، إذا كنت لا تستخدمين أي وسيلة لمنع الحمل ، تعتقدين أنك قد تكون حاملا أو تخططين لإنجاب طفل ، اسألي طبيبك أو الصيدلي للحصول على المشورة قبل تناول هذا الدواء.</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">إذا شعرت بالدوخة أو الضعف أو النعاس مع هذا الدواء ، فلا يجوز قيادة السيارة أو تشغيل الآلات.</p><p dir="RTL"><strong>محتوي لرتيف من اللاكتوز</strong></p><p dir="RTL">إذا أخبرك طبيبك أن لديك حساسية تجاه بعض السكريات ، فاتصل بطبيبك قبل تناول هذا المنتج الطبي.</p><p dir="RTL"><strong>محتوي لرتيف من الصوديوم</strong></p><p dir="RTL">يحتوي هذا الدواء على أقل من 1 مليمول صوديوم (23 ملجرام) لكل قرص ، وهذا يعني بشكل أساسي &quot;خالٍ من الصوديوم&quot;.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احرص دائمًا على تناول هذا الدواء تمامًا كما أخبرك طبيبك. استشر طبيبك أو الصيدلي إذا لم تكن متأكدًا.</p><p dir="RTL"><strong>الكبار</strong>: الجرعة الموصى بها هي 10 ملجرام مرة واحدة يومياً في نفس الوقت كل يوم ويفضل في الصباح قبل الإفطار بـ 15 دقيقة على الأقل. قد ينصحك طبيبك بزيادة الجرعة لرتيف إلى قرص واحد 20 ملجرام يوميًا ، إذا لزم الأمر. (انظر القسم 2 &quot;تناول لرتيف مع الطعام والشراب والكحول&quot;).</p><p dir="RTL">لرتيف 10 ملجرام: خط التقسيم هو فقط لتسهيل الكسر لسهولة البلع وليس للتقسيم إلى جرعات متساوية.</p><p dir="RTL">لرتيف 20 ملجرام: يمكن تقسيم القرص إلى جرعات متساوية.</p><p dir="RTL">يفضل ابتلاع الأقراص كاملة مع القليل من الماء.</p><p dir="RTL"><strong>الاستخدام في الأطفال:</strong> لا ينبغي استخدام هذا الدواء للأطفال دون سن 18 عامًا.</p><p dir="RTL"><strong>المرضى المسنون:</strong> لا داعي لتعديل الجرعة اليومية. ومع ذلك ، يجب توخي الحذر عند بدء العلاج.</p><p dir="RTL"><strong>المرضى الذين يعانون من مشاكل في الكبد أو الكلى:</strong> هناك حاجة إلى عناية خاصة عند بدء العلاج عند هؤلاء المرضى ويجب التعامل بحذر مع زيادة الجرعة اليومية إلى 20 ملجرام.</p><p dir="RTL"><strong>تناول جرعة زائدة من لرتيف أقراص</strong></p><p dir="RTL">لا تتجاوز الجرعة الموصوفة. إذا تناولت أكثر من الجرعة الموصوفة ، تحدث إلى طبيبك أو اذهب إلى المستشفى على الفور. خذ علبة الدواء معك. يمكن أن يؤدي تناول أكثر من الجرعة الصحيحة إلى انخفاض مفرط في ضغط الدم ويمكن أن ينبض قلبك بشكل غير منتظم أو أسرع.</p><p dir="RTL"><strong>إذا نسيت أن تتناول لرتيف أقراص</strong></p><p dir="RTL">إذا نسيت تناول جرعة من لرتيف ، فتجاوز الجرعة الفائتة ثم استمر كما كان من قبل. لا تتناول جرعة مضاعفة لتعويض الجرعة المنسية.</p><p dir="RTL"><strong>التوقف عن تناول لرتيف أقراص</strong></p><p dir="RTL">إذا توقفت عن تناول لرتيف ، فقد يرتفع ضغط دمك مرة أخرى. يرجى استشارة طبيبك قبل التوقف عن العلاج.</p><p dir="RTL">إذا كان لديك أي أسئلة أخرى حول استخدام هذا الدواء ، اسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية ، يمكن أن يسبب هذا الدواء آثارًا جانبية ، على الرغم من عدم حدوثها لدى الجميع. الآثار الجانبية التالية قد تحدث مع هذا الدواء:</p><p dir="RTL">بعض الآثار الجانبية يمكن أن تكون خطيرة.</p><p dir="RTL">في حالة حدوث أي مما يلي ، أخبر طبيبك على الفور:</p><p dir="RTL">نادر (قد يؤثر على حتى 1 من كل 1000 شخص): الذبحة الصدرية (مثل ضيق الصدر بسبب نقص الدم في القلب) ، تفاعلات الحساسية (تشمل الأعراض الحكة ، الطفح الجلدي ، الشرى) ، الإغماء.</p><p dir="RTL">قد يعاني المرضى الذين يعانون من الذبحة الصدرية الموجودة مسبقًا من زيادة وتيرة هذه النوبات أو مدتها أو شدتها مع مجموعة الأدوية التي ينتمي إليها لرتيف. يمكن ملاحظة حالات نوبة قلبية متفرقة.</p><p dir="RTL">الآثار الجانبية المحتملة الأخرى:</p><p dir="RTL">شائعة (قد تظهر لدى حتى 1 من كل 10 أشخاص): صداع ، سرعة دقات القلب ، الشعور بنبض قلب سريع أو غير منتظم (خفقان) ، احمرار مفاجئ في وجهك ، رقبتك أو أعلى صدرك (احمرار) ، تورم الكاحل.</p><p dir="RTL">غير شائعة (قد تظهر لدى حتى 1 من كل 100 شخص): دوار ، هبوط في ضغط الدم ، حرقة ، الشعور بالغثيان ، آلام في المعدة ، طفح جلدي ، حكة ، ألم عضلي ، خروج كميات كبيرة من البول ، الشعور بالضعف أو الشعور بالتعب.</p><p dir="RTL">نادرة (قد تؤثر على حتى 1 من كل 1000 شخص): نعاس ، قيء ، إسهال ، خلايا ، زيادة في مرات التبول عن العدد المعتاد ، ألم في الصدر.</p><p dir="RTL">غير معروف (لا يمكن تقدير معدل التكرار من البيانات المتاحة): تورم اللثة ، تغيرات في وظائف الكبد (تم الكشف عنها عن طريق اختبارات الدم) ، ظهور سائل عكر (عند إجراء غسيل الكلى من خلال أنبوب في البطن) ، تورم وجهك ، والشفتين واللسان أو الحلق مما قد يسبب صعوبة في التنفس أو البلع.</p><p><strong>الإبلاغ عن الآثار الجانبية: </strong></p><p>إذا زادت حدة أي من هذه الأعراض الجانبية ، أو لاحظت ظهور أعراض جانبية غير ما تم ذكره في هذه النشرة ، يرجى إبلاغ الطبيب المعالج أو الصيدلي. وهذا يشمل أي آثار جانبية محتملة غير مدرجة في هذه النشرة. يمكنك أيضا الإبلاغ عن الآثار الجانبية مباشرة. بالإبلاغ عن الآثار الجانبية يمكنك المساعدة في توفير مزيد من المعلومات حول أمان هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>للإبلاغ حول الأعراض الجانبية التي قد تحدث يرجى التواصل عبر العناوين التالية</strong><strong>:</strong></p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>المملكة العربية السعودية:</strong></p><table dir="rtl" border="0" cellspacing="0" cellpadding="0" style="width:553px"><tbody><tr><td style="vertical-align:top"><p dir="RTL">المركز الوطني للتيقظ الدوائي (NPC)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مركز الاتصال بالهيئة العامة للغذاء والدواء 19999:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البريد الإلكتروني npc.drug@sfda.gov.sa:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الموقع الإلكتروني: https://ade.sfda.gov.sa</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>دول الخليج العربي الأخرى:</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">الرجاء الاتصال بالجهات الوطنية في كل دولة.</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>&nbsp;</strong><strong>&nbsp;</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحفظ في درجة حرارة أقل من 30 درجة مئوية.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احفظ هذا الدواء بعيدًا عن رؤية ومتناول أيدي الأطفال.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على العبوة بعد EXP. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من الشهر.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تتخلص من الأدوية في مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. ستساعد هذه الإجراءات في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ماذا يحتوي لرتيف أقراص على:</strong></p><p dir="RTL">المادة الفعالة هي ليركانيديبين هيدروكلوريد هيمي هيدرات</p><p dir="RTL"><strong>لرتيف أقراص </strong><strong>10 ملجرام</strong></p><p dir="RTL">يحتوي كل قرص مغلف بطبقة رقيقة على 10 ملجرام من ليركانيديبين هيدروكلوريد على هيئة هيمي هيدرات.</p><p dir="RTL"><strong>لرتيف أقراص </strong><strong>20 </strong><strong>ملجرام</strong></p><p dir="RTL">يحتوي كل قرص مغلف بطبقة رقيقة على 20 ملجرام من ليركانيديبين هيدروكلوريد على هيئة هيمي هيدرات.</p><p dir="RTL"><strong>الصواغات الأخرى في لرتيف أقراص </strong><strong>10 </strong><strong>ملجرام</strong><strong>:</strong></p><p dir="RTL">اللاكتوز أحادي الهيدرات ، السليلوز دقيق التبلور، جلايكولات نشا الصوديوم النوع A (Primojel) (Part- I} ؛ البوفيدون ، السليلوز دقيق التبلور، جلايكولات نشا الصوديوم النوع A (Primojel) (Part- II} ستيرات الماغنيسيوم.</p><p dir="RTL"><strong>الصواغات الأخرى لطبقة الطلاء الخارجية:</strong></p><p dir="RTL">كحول&nbsp;عديد الفاينيل المتحلل جزئيا ؛ ثاني أكسيد التيتانيوم ؛ ماكروجول / PEG ؛ تلك ؛ أكسيد الحديد الأصفر.</p><p dir="RTL"><strong>الصواغات الأخرى في لرتيف أقراص </strong><strong>20</strong> <strong>ملجرام</strong><strong>:</strong></p><p dir="RTL">اللاكتوز أحادي الهيدرات ، السليلوز دقيق التبلور، جلايكولات نشا الصوديوم النوع A (Primojel) (Part- I} ؛ البوفيدون ، السليلوز دقيق التبلور، جلايكولات نشا الصوديوم النوع A (Primojel) (Part- II} ستيرات الماغنيسيوم.</p><p dir="RTL"><strong>الصواغات الأخرى لطبقة الطلاء الخارجية:</strong></p><p dir="RTL">كحول&nbsp;عديد الفاينيل المتحلل جزئيا ؛ ثاني أكسيد التيتانيوم ؛ ماكروجول / PEG ؛ تلك ؛ أكسيد الحديد الأحمر.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ما هو شكل </strong><strong>لرتيف</strong><strong> </strong><strong>أقراص؟</strong></p><p dir="RTL"><strong>لرتيف أقراص </strong><strong>10 </strong><strong>ملجرام</strong><strong>:</strong></p><p dir="RTL">أقراص صفراء مستديرة مغلفة بطبقة رقيقة ومحدبة من الجانبين مدموغ عليها &quot;3&quot; و &quot;4&quot; على جانبي خط التقسيم على وجه واحد و &quot;HL&quot; من الجانب الآخر.</p><p dir="RTL"><strong>لرتيف أقراص </strong><strong>20</strong> <strong>ملجرام</strong><strong>:</strong></p><p dir="RTL">أقراص مستديرة مغلفة بطبقة رقيقة باللون الوردي إلى الخوخي ومحدبة من الجانبين مدموغ عليها &quot;3&quot; و &quot;5&quot; على جانبي خط التقسيم على وجه واحد و &quot;HL&quot; من الجانب الآخر.</p><p dir="RTL"><strong>كيفية توفير </strong><strong>لرتيف</strong><strong> </strong><strong>أقراص؟</strong></p><p dir="RTL">يتم توفير لرتيف أقراص في علبة تحتوي على 10 أقراص من شريط من PVC/Aclar-Alu</p><p dir="RTL">لرتيف 10 ملجرام ــ 30 قرص و 60 قرص.</p><p dir="RTL">لرتيف 20 ملجرام ــ 30 قرص و 60 قرص.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p><strong>صاحب حق التسويق والشركة المصنعة:</strong></p><p dir="RTL"><strong>شركة اماروكس السعودية الصناعية</strong></p><p>شارع الجامعة ، الملز</p><p>الرياض 12629، المملكة العربية السعودية</p><p dir="RTL">تليفون: +966112268850</p><p dir="RTL"><strong>الشركة المصنعة: </strong></p><p dir="RTL">شركة هيتيرو لاب الوحدة الخامسة، الهند</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة في يونيو 2023 ، نسخة 1 
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Lertiv 10 and 20 (Lercanidipine Hydrochloride Film-Coated Tablets 10mg and 20mg)
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Lercanidipine Hydrochloride Film-Coated Tablets 10mg :
Each film coated tablet contains: Lercanidipine Hydrochloride (as Hemihydrate) 10mg.
Lercanidipine Hydrochloride Film-Coated Tablets 20mg :
Each film coated tablet contains: Lercanidipine Hydrochloride (as Hemihydrate) 20mg.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-Coated Tablets
Lertiv 10 (Lercanidipine Hydrochloride Film-Coated Tablets 10mg)
Yellow, film coated, round shaped, biconvex tablets debossed with '3' and '4' on either side of score line on one side of tablet and "HL" on the other side.
Lertiv 20 (Lercanidipine Hydrochloride Film-Coated Tablets 20mg)
Pink to peach, film coated, round shaped, biconvex tablets debossed with '3' and '5' on either side of score line on one side of tablet and "HL" on the other side.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lercanidipine Hydrochloride is indicated in adults for the treatment of mild to moderate essential hypertension.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Posology</p><p>The recommended dosage is 10 mg orally once a day at least 15 minutes before meals; the dose may be increased to20 mg depending on the individual patient&#39;s response.</p><p>Dose titration should be gradual, because it may take about 2 weeks before the maximal antihypertensive effect is apparent.</p><p>Some individuals, not adequately controlled on a single antihypertensive agent, may benefit from the addition of Lercanidipine Hydrochloride to therapy with a beta-adrenoceptor blocking drug (atenolol), a diuretic (hydrochlorothiazide) or an angiotensin converting enzyme inhibitor</p><p>&nbsp;</p><p>(captopril or enalapril).</p><p>Since the dose-response curve is steep with a plateau at doses between 20-30 mg, it is unlikely that efficacy will be improved by higher doses; whereas side effects may increase.</p><p><em>Elderly patients: </em>although the pharmacokinetic data and clinical experience suggest that no adjustment of the daily dosage is required, special care should be exercised when initiating treatment in the elderly.</p><p><em>Paediatric population: </em>the safety and efficacy of Lercanidipine Hydrochloride in children aged up to 18 years have not been established.</p><p>No data are available.</p><p><em>Patients with renal or hepatic impairment: </em>special care should be exercised when treatment is commenced in patients with mild to moderate renal or hepatic dysfunction. Although the usually recommended dose schedule may be tolerated by these subgroups, an increase in dose to 20 mg daily must be approached with caution. The antihypertensive effect may be enhanced in patients with hepatic impairment and consequently an adjustment of the dosage should be considered.</p><p>Lercanidipine Hydrochloride is contraindicated in patients with severe hepatic impairment or in patients with severe renal impairment ( GFR&lt; 30 ml/min), including patients undergoing dialysis (see sections 4.3 and 4.4).</p><p>Method of administration</p><p>Precautions to be taken before handling or administering the medicinal product:</p><p>-&nbsp;&nbsp;&nbsp; Treatment should be preferably administered in the morning at least 15 minutes before breakfast.</p><p>-&nbsp; This product should not been administered with grapefruit juice (see section 4.3 and 4.5).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
•	Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
•	Left ventricular outflow tract obstruction.
•	Untreated congestive cardiac failure.
•	Unstable angina pectoris or recent (within 1 month) myocardial infarction.
•	Severe hepatic impairment.
•	Severe renal impairment (GFR < 30 ml/min), including patients undergoing dialysis
•	Co-administration with:
•	strong inhibitors of CYP3A4 (see section 4.5),
 
•	ciclosporin (see section 4.5),
•	grapefruit or grapefruit juice (see section 4.5).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Sick-sinus syndrome</u></p><p>Lercanidipine should be administered with caution in patients with sick sinus syndrome (without a pacemaker).</p><p><u>Left ventricular dysfunction</u></p><p>Although hemodynamic controlled studies revealed no impairment of ventricular function, care is required in patients with left ventricular dysfunction.</p><p><u>Ischaemic heart disease</u></p><p>It has been suggested that some short-acting dihydropyridines may be associated with increased cardiovascular risk in patients with ischaemic heart disease. Although lercanidipine is long- acting, caution is required in such patients. Some dihydropyridines may rarely lead to precordial pain or angina pectoris. Very rarely patients with pre-existing anginapectoris may experience increased frequency, duration or severity of these attacks. Isolated cases of myocardialinfarction may be observed (see section 4.8).</p><p><u>Use in renal or hepatic impairment</u></p><p>Special care should be exercised when treatment is commenced in patients with mild to moderate renal impairment. Although the usual recommended dose of 10 mg daily may be tolerated, an increase to 20 mg daily should be approached with caution.</p><p>The antihypertensive effect may be enhanced in patients with moderate hepatic impairment and consequently an adjustment of the dosage should be considered.</p><p>Lercanidipine is contraindicated in patients with severe hepatic impairment or renal impairment (GFR &lt; 30 ml/min),including patients undergoing haemodialysis (see section 4.2 and section 4.3).</p><p><u>Peritoneal Dialysis</u></p><p>Lercanidipine has been associated with the development of cloudy peritoneal effluent in patients on peritoneal dialysis. The turbidity is due to an increased triglyceride concentration in the peritoneal effluent. Whilst the mechanism is unknown, the turbidity tends to resolve soon after withdrawal of lercanidipine. This is an important association to recognise as cloudy peritoneal</p><p>&nbsp;</p><p>effluent can be mistaken for infective peritonitis with consequential unnecessary hospitalisation and empiric antibiotic administration.</p><p><u>Inducers of CYP3A4</u></p><p>Inducers of CYP3A4 like anticonvulsants (e.g. phenytoin, carbamazepine) and rifampicin may reduce lercanidipine plasma levels and therefore the efficacy of lercanidipine may be less than expected (see section 4.5).</p><p><u>Alcohol</u></p><p>Alcohol should be avoided since it may potentiate the effect of vasodilating antihypertensive drugs (see section 4.5).</p><p><u>Lactose</u></p><p>This medicine contains lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.</p><p><u>Sodium</u></p><p>This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially &ldquo;sodium-free&rdquo;.</p><p><u>Paediatric population</u></p><p>The safety and efficacy of Lercanidipine Hydrochloride have not been demonstrated in children.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>1.1&nbsp;&nbsp; Contraindications of concomitant use</p><p><u>Inhibitors of CYP3A4</u></p><p>Lercanidipine is known to be metabolised by the CYP3A4 enzyme and therefore inhibitors of CYP3A4 administered concurrently may interact with the metabolism and elimination of lercanidipine. An interaction study with a strongCYP3A4 inhibitor, ketoconazole, has shown a considerable increase in plasma levels of lercanidipine (a 15-foldincrease of the AUC and an 8- fold increase of the C for the eutomer S-lercanidipine).</p><p>Co-prescription of lercanidipine with inhibitors of CYP3A4 (e.g. ketoconazole, itraconazole, ritonavir, erythromycin, troleandomycin, clarithromycin) should be avoided (see section 4.3).</p><p><u>Ciclosporin</u></p><p>Increased plasma levels of both lercanidipine and ciclosporin have been observed following concomitant administration. A study in young healthy volunteers has shown that when ciclosporin was administered 3 hours after the Lercanidipine intake, the plasma levels of</p><p>&nbsp;</p><p>lercanidipine did not change, while the AUC of ciclosporin increased by 27%. However, the co- administration of lercanidipine with ciclosporin has caused a 3-fold increase of the plasma levels of lercanidipine and a 21% increase of the ciclosporin AUC.</p><p>Ciclosporin and lercanidipine should not be administered together (see section 4.3). <u>Grapefruit or grapefruit juice</u></p><p>As for other dihydropyridines, lercanidipine is sensitive to inhibition of metabolism by grapefruit or grapefruit juice, with a consequent rise in its systemic availability and increased hypotensive effect. Lercanidipine should not be taken with grapefruit or grapefruit juice (see section 4.3).</p><p>Concomitant use not recommended</p><p><u>Inducers of CYP3A4</u></p><p>Co-administration of lercanidipine with CYP3A4 inducers like anticonvulsants (e.g. phenytoin, phenobarbital, carbamazepine) and rifampicin should be approached with caution since the antihypertensive effect may be reduced and blood pressure should be monitored more frequently than usual (see section 4.4).</p><p><u>Alcohol</u></p><p>Alcohol should be avoided since it may potentiate the effect of vasodilating antihypertensive drugs (see section 4.4).</p><p>Precautions including dose adjustment</p><p><u>Substrates of CYP3A4</u></p><p>Caution should be exercised when lercanidipine is co-prescribed with other substrates of CYP3A4, like terfenadine, astemizole, class III antiarrhythmic drugs such as amiodarone, quinidine, sotalol.</p><p><u>Midazolam</u></p><p>When concomitantly administered at a dose of 20 mg with midazolam p.o. to elderly volunteers, Lercanidipine absorption was increased (by approximately 40%) and the rate of absorption was decreased (t was delayed from1.75 to 3 hours). Midazolam concentrations were not modified.</p><p><u>Metoprolol</u></p><p>When lercanidipine was co-administered with metoprolol, a &beta;-blocker eliminated mainly by the liver, the bioavailability of metoprolol was not changed while that of lercanidipine was reduced by 50%. This effect may be due to the reduction in the hepatic blood flow caused by &beta;-blockers</p><p>&nbsp;</p><p>and may therefore occur with other drugs of this class. Consequently, lercanidipine may be safely administered with &beta;-adrenoceptor blocking drugs, but dose adjustment may be required.</p><p><u>Digoxin</u></p><p>Co-administration of 20 mg lercanidipine in patients chronically treated with &beta;-methyldigoxin showed no evidence of pharmacokinetic interaction. However, a mean increase of 33% in digoxin C was observed, while AUC and renal clearance were not significantly modified. Patients on concomitant digoxin treatment should be closely monitored clinically for signs of digoxin toxicity.</p><p>Concomitant use with other drugs</p><p><u>Fluoxetine</u></p><p>An interaction study with fluoxetine (an inhibitor of CYP2D6 and CYP3A4), conducted in volunteers of an age of 65 &plusmn; 7years (mean &plusmn; s.d.), has shown no clinically relevant modification of the pharmacokinetics of lercanidipine.</p><p><u>Cimetidine</u></p><p>Concomitant administration of cimetidine 800 mg daily does not cause significant modifications in plasma levels of lercanidipine, but at higher doses caution is required since the bioavailability and the hypotensive effect of Lercanidipine may be increased.</p><p><u>Simvastatin</u></p><p>When a dose of 20 mg of Lercanidipine was repeatedly co-administered with 40 mg of simvastatin, the AUC of Lercanidipine was not significantly modified, while simvastatin AUC increased by 56% and that of its active metabolite&beta;-hydroxyacid by 28%. It is unlikely that such changes are of clinical relevance. No interaction is expected when Lercanidipine is administered in the morning and simvastatin in the evening, as indicated for such drug.</p><p><u>Diuretics and ACE inhibitors</u></p><p>Lercanidipine has been safely administered with diuretics and ACE inhibitors. <u>Other medications affecting blood pressure</u></p><p>As for all antihypertensive medications, an increased hypotensive effects may be observed when Lercanidipine is administered with other medications affecting blood pressure, such as alpha blockers for the treatment of urinary symptoms, tricyclic antidepressants, neuroleptics. On the contrary, a reduction of the hypotensive effect may be observed with a concomitant use with corticosteroids.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>There are no data from the use of Lercanidipine in pregnant women. Studies in animals have not shown teratogenic effects (see section 5.3), but these have been observed with other dihydropyridine compounds. Lercanidipine Hydrochloride is not recommended during pregnancy and in women of childbearing-potential not using contraception.</p><p><u>Breast-feeding</u></p><p>It is unknown whether Lercanidipine/metabolites are excreted in human milk. A risk to the newborns/infants cannot be excluded. Lercanidipine Hydrochloride should not be used during breast-feeding.</p><p>Fertility</p><p>No clinical data are available with Lercanidipine. Reversible biochemical changes in the head of spermatozoa which can impair fecundation have been reported in some patients treated by channel blockers. In cases where repeated in-vitro fertilization is unsuccessful and where another explanation cannot be found, the possibility of calcium channel blockers as the cause should be considered.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lercanidipine Hydrochloride has minor influence on the ability to drive and use machines. However, caution should be exercised because dizziness, asthenia, fatigue and rarely somnolence may occur.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of safety profile</u></p><p>&nbsp;</p><p>The safety of Lercanidipine at a dose of 10-20 mg once daily has been evaluated in double-blind, placebo-controlled clinical trials (with 1200 patients receiving Lercanidipine and 603 patients receiving placebo) and in active-controlled and uncontrolled long term clinical trials on a total of 3676 hypertensive patients receiving Lercanidipine.</p><p>The most commonly reported adverse reactions in clinical trials and in the post-marketing experience are: peripheral oedema, headache, flushing, tachycardia and palpitations.</p><p><u>Tabulated list of adverse reactions</u></p><p>&nbsp;</p><p>&nbsp;</p><p><!--[if mso & !supportInlineShapes & supportFields]><span
style='font-size:1.0pt;mso-bidi-font-size:12.0pt'><span style='mso-element:
field-begin;mso-field-lock:yes'></span><span style='mso-spacerun:yes'> </span>SHAPE
<span style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:
field-separator'></span></span><![endif]--><!--[if gte vml 1]><v:group id="_x0000_s2050"
 style='width:471.55pt;height:.75pt;mso-position-horizontal-relative:char;
 mso-position-vertical-relative:line' coordsize="9431,15">
 <v:line id="_x0000_s2051" style='position:absolute' from="71,8" to="9431,8"/>
 <v:line id="_x0000_s2052" style='position:absolute' from="71,8" to="9431,8"/>
 <v:line id="_x0000_s2053" style='position:absolute' from="71,8" to="9431,8"/>
 <v:line id="_x0000_s2054" style='position:absolute' from="71,8" to="9431,8"/>
 <v:line id="_x0000_s2055" style='position:absolute' from="71,8" to="9431,8"/>
 <v:line id="_x0000_s2056" style='position:absolute' from="0,8" to="9431,8"/>
 <w:wrap type="none"/>
 <w:anchorlock/>
</v:group><![endif]--><img width="631" height="1" src="file:///C:/Users/Lenovo/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><![endif]--><!--[if mso & !supportInlineShapes & supportFields]><span
style='font-size:1.0pt;mso-bidi-font-size:12.0pt'><v:shape id="_x0000_i1025"
 type="#_x0000_t75" style='width:471.55pt;height:.75pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span></span><![endif]--></p><p>In the table below, adverse reactions reported in clinical trials and in the worldwide post- marketing experience for which a reasonable causal relationship exists are listed by MedDRA system organ class and frequency: very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000), not known (cannot be estimated from the available data). Within each frequency grouping the observed adverse reactions are presented in order of decreasing seriousness.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>MedDRA&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p></td><td style="vertical-align:top"><p><strong>Rare</strong></p></td><td style="vertical-align:top"><p><strong>Not known</strong></p></td></tr><tr><td style="vertical-align:top"><p>Immune&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypersensitivity</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Nervous&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; system disorders</p></td><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>Dizziness</p></td><td style="vertical-align:top"><p>Somnolence Syncope</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>Tachycardia Palpitations</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Angina pectoris</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>Flushing</p></td><td style="vertical-align:top"><p>Hypotension</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Dyspepsia Nausea</p><p>Abdominal&nbsp;&nbsp;&nbsp;&nbsp; pain upper</p></td><td style="vertical-align:top"><p>Vomiting Diarrhoea</p></td><td style="vertical-align:top"><p>Gingival hypertrophy1 Peritoneal&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cloudy effluent1</p></td></tr><tr><td style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Serum transaminase increased1</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rash Pruritus</p></td><td style="vertical-align:top"><p>Urticaria</p></td><td style="vertical-align:top"><p>Angioedema1</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tissue disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Myalgia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Renal&nbsp;&nbsp;&nbsp;&nbsp; and&nbsp;&nbsp;&nbsp;&nbsp; urinary disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Polyuria</p></td><td style="vertical-align:top"><p>Pollakiuria</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>General disorders and</p><p>administration&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; site conditions</p></td><td style="vertical-align:top"><p>Oedema peripheral</p></td><td style="vertical-align:top"><p>Asthenia Fatigue</p></td><td style="vertical-align:top"><p>Chest pain</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>1adverse reactions from spontaneous reporting in the worldwide post-marketing experience <u>Description of selected adverse reactions</u></p><p>In placebo controlled clinical trials the incidence of peripheral oedema was 0.9% with Lercanidipine 10-20 mg and 0.83% with placebo. This frequency reached 2% in the overall study population including long term clinical trials.</p><p>Lercanidipine does not appear to influence adversely blood sugar or serum lipid levels.</p><p>&nbsp;</p><p>Some dihydropyridine may rarely lead to precordial pain or angina pectoris. Very rarely patients with pre-existing angina pectoris may experience increased frequency, duration or severity of these attacks. Isolated cases of myocardial infarction may be observed.</p><p><u>Reporting of suspected adverse reactions</u></p><p>&nbsp;</p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions (see details below)</p><p><u>Reporting of suspected adverse reactions</u></p><p>&nbsp;</p><p>&bull;&nbsp; Saudi Arabia<em>:</em></p><p><strong><em>&nbsp;</em></strong></p><p><!--[if gte vml 1]><o:wrapblock><v:shapetype
  id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
  <v:stroke joinstyle="miter"/>
  <v:path gradientshapeok="t" o:connecttype="rect"/>
 </v:shapetype><v:shape id="_x0000_s2057" type="#_x0000_t202" style='position:absolute;
  margin-left:84.6pt;margin-top:9.55pt;width:383.8pt;height:129pt;z-index:-251651072;
  mso-wrap-distance-left:0;mso-wrap-distance-right:0;
  mso-position-horizontal-relative:page' filled="f" strokeweight=".16969mm">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoBodyText style='margin-top:0in;margin-right:68.25pt;
     margin-bottom:0in;margin-left:5.15pt;margin-bottom:.0001pt;line-height:
     150%'>The National Pharmacovigilance and Drug Safety Centre (NPC) o Fax:
     +966-11-205-7662<o:p></o:p></p>
     <p class=MsoBodyText style='margin-left:5.15pt'>o Call NPC at
     +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.<o:p></o:p></p>
     <p class=MsoBodyText style='margin-top:6.55pt;margin-right:0in;margin-bottom:
     0in;margin-left:14.15pt;margin-bottom:.0001pt;text-indent:-9.05pt;
     mso-list:l0 level1 lfo1;tab-stops:14.2pt'><![if !supportLists]><span
     style='letter-spacing:-.05pt'><span style='mso-list:Ignore'>o<span
     style='font:7.0pt "Times New Roman"'>&nbsp; </span></span></span><![endif]><span
     dir=LTR></span>Toll free phone:<span style='letter-spacing:-.1pt'> </span>8002490000<o:p></o:p></p>
     <p class=MsoBodyText style='margin-top:6.95pt;margin-right:0in;margin-bottom:
     0in;margin-left:14.15pt;margin-bottom:.0001pt;text-indent:-9.05pt;
     mso-list:l0 level1 lfo1;tab-stops:14.2pt'><![if !supportLists]><span
     style='letter-spacing:-.05pt'><span style='mso-list:Ignore'>o<span
     style='font:7.0pt "Times New Roman"'>&nbsp; </span></span></span><![endif]><span
     dir=LTR></span>E-mail:<span style='letter-spacing:-.05pt'> </span><a
     href="mailto:npc.drug@sfda.gov.sa"><span style='color:blue;text-decoration:
     none;text-underline:none'>npc.drug@sfda.gov.sa</span></a><o:p></o:p></p>
     <p class=MsoBodyText style='margin-top:6.85pt;margin-right:0in;margin-bottom:
     0in;margin-left:14.15pt;margin-bottom:.0001pt;text-indent:-9.05pt;
     mso-list:l0 level1 lfo1;tab-stops:14.2pt'><![if !supportLists]><span
     style='letter-spacing:-.05pt'><span style='mso-list:Ignore'>o<span
     style='font:7.0pt "Times New Roman"'>&nbsp; </span></span></span><![endif]><span
     dir=LTR></span>Website:<span style='letter-spacing:-.05pt'> </span><a
     href="http://www.sfda.gov.sa/npc"><span style='color:blue;text-decoration:
     none;text-underline:none'>www.sfda.gov.sa/npc</span></a><o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="516" height="176" alt="Text Box: The National Pharmacovigilance and Drug Safety Centre (NPC) o Fax: +966-11-205-7662
o Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.
o	Toll free phone: 8002490000
o	E-mail: npc.drug@sfda.gov.sa
o	Website: www.sfda.gov.sa/npc
" src="file:///C:/Users/Lenovo/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p>&nbsp;</p><p><strong>o Other GCC States:</strong></p><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the post-marketing experience of Lercanidipine, some cases of overdose have been reported ranging from 30-40 mg up to 800 mg, including reports of suicide attempt.</p><p>Symptoms</p><p><strong>&nbsp;</strong></p><p>As with other dihydropyridine, Lercanidipine over dosage results in excessive peripheral vasodilation with marked hypotension and reflex tachycardia. However, at very high doses, the peripheral selectivity may be lost, causing bradycardia and a negative inotropic effect. The most common ADRs associated to cases of overdose have been hypotension, dizziness, headache and palpitations.</p><p>Management</p><p>&nbsp;</p><p>Clinically significant hypotension requires active cardiovascular support including frequent monitoring of cardiac and respiratory function, elevation of extremities and attention to circulating fluid volume and urine output. In view of the prolonged pharmacological effect of Lercanidipine, it is essential that the cardiovascular status of the patient is monitored for 24 hours at least. Since the product has a high protein binding, dialysis is not likely to be effective. Patients in whom a moderate to severe intoxication is anticipated should be observed in a high- care setting.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group:</p><p>&nbsp;</p><p>Selective calcium channel blockers with mainly vascular effects &ndash; Dihydropyridine derivatives ATC code: C08CA13</p><p><u>Mechanism of action</u></p><p>&nbsp;</p><p>Lercanidipine is a calcium antagonist of the dihydropyridine group and inhibits the transmembrane influx of calcium into cardiac and smooth muscle. The mechanism of its antihypertensive action is due to a direct relaxant effect on vascular smooth muscle thus lowering total peripheral resistance.</p><p>&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p>&nbsp;</p><p>Despite its short pharmacokinetic plasma half-life, Lercanidipine is endowed with a prolonged antihypertensive activity because of its high membrane partition coefficient, and is devoid of negative inotropic effects due to its high vascular selectivity.</p><p>Since the vasodilatation induced by Lercanidipine Hydrochloride is gradual in onset, acute hypotension with reflex tachycardia has rarely been observed in hypertensive patients.</p><p>As for other asymmetric 1,4-dihydropyridines, the antihypertensive activity of Lercanidipine is mainly due to its (S)-enantiomer.</p><p><u>Clinical efficacy and safety</u></p><p>&nbsp;</p><p>The clinical efficacy and safety of Lercanidipine at a dose of 10-20 mg once daily has been evaluated in double-blind, placebo-controlled clinical trials (with 1200 patients receiving Lercanidipine and 603 patients receiving placebo) and in active-controlled and uncontrolled long term clinical trials on a total of 3676 hypertensive patients.</p><p>Most clinical trials have been conducted in patients with mild to moderate essential hypertension (including elderly and diabetic patients), receiving Lercanidipine alone or in combination with ACE-Is, diuretics or beta-blockers.</p><p>In addition to the clinical studies conducted to support the therapeutic indications, a further small uncontrolled but randomised study of patients with severe hypertension (mean <u>+</u> SD diastolic blood pressure of 114.5 <u>+</u> 3.7 mmHg) showed that blood pressure was normalised in 40% of the 25 patients on 20 mg once daily dose and in 56% of 25 patients on 10 mg twice daily doses of Lercanidipine Hydrochloride. In a double-blind, randomised, controlled study versus placebo in patients with isolated systolic hypertension Lercanidipine Hydrochloride was efficacious in lowering systolic blood pressure from mean initial values of 172.6 <u>+</u> 5.6 mmHg to 140.2 <u>+</u> 8.7 mmHg.</p><p><u>Paediatric population</u></p><p>&nbsp;</p><p>No clinical trial has been performed in the paediatric population.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>Lercanidipine Hydrochloride is completely absorbed after 10-20 mg oral administration and peak plasma levels, 3.30 ng/ml <u>+</u> 2.09 s.d. and 7.66 ng/ml <u>+</u> 5.90 s.d. respectively, occur about 1.5-3 hours after dosing.</p><p>The two enantiomers of lercanidipine show a similar plasma level profile: the time to peak plasma concentration is the same, the peak plasma concentration and AUC are, on average, 1.2- fold higher for the (S) enantiomer and the elimination half-lives of the two enantiomers are essentially the same. No &quot;in vivo&quot; interconversion of enantiomers is observed.</p><p>Due to the high first pass metabolism, the absolute bioavailability of Lercanidipine Hydrochloride orally administered to patients under fed conditions is around 10%, although it is reduced to 1/3 when administered to healthy volunteers under fasting conditions.</p><p>Oral availability of lercanidipine increases 4-fold when Lercanidipine Hydrochloride is ingested up to 2 hours after a high fat meal. Accordingly, Lercanidipine Hydrochloride should be taken before meals.</p><p><u>Distribution</u></p><p>Distribution from plasma to tissues and organs is rapid and extensive.</p><p>The degree of serum protein binding of lercanidipine exceeds 98%. Since plasma protein levels are reduced in patients with severe renal or hepatic dysfunction, the free fraction of the drug may be increased.</p><p><u>Biotransformation</u></p><p>Lercanidipine Hydrochloride is extensively metabolised by CYP3A4; no parent drug is found in the urine or the faeces. It is predominantly converted to inactive metabolites and about 50% of the dose is excreted in the urine.</p><p><em>&ldquo;In vitro&rdquo; </em>experiments with human liver microsomes have demonstrated that lercanidipine shows some degree of inhibition of CYP3A4 and CYP2D6, at concentrations 160- and 40-fold, respectively, higher than those reached at peak in the plasma after the dose of 20 mg.</p><p>Moreover, interaction studies in humans have shown that lercanidipine did not modify the plasma levels of midazolam, a typical substrate of CYP3A4, or of metoprolol, a typical substrate of CYP2D6. Therefore, inhibition of biotransformation of drugs metabolised by CYP3A4 and CYP2D6 by Lercanidipine Hydrochloride is not expected at therapeutic doses.</p><p><u>Elimination</u></p><p>&nbsp;</p><p>Elimination occurs essentially by biotransformation. A mean terminal elimination half life of 8- 10 hours was calculated and the therapeutical activity lasts for 24 hours because of its high binding to lipid membrane. No accumulation was seen upon repeated administration.</p><p><u>Linearity/non linearity</u></p><p>Oral administration of Lercanidipine Hydrochloride leads to plasma levels of lercanidipine not directly proportional to dosage (non-linear kinetics). After 10, 20 or 40 mg, peak plasma concentrations observed were in the ratio 1:3:8 and areas under plasma concentration-time curves in the ratio 1:4:18, suggesting a progressive saturation of first pass metabolism. Accordingly, availability increases with dosage elevation.</p><p><u>Special populations</u></p><p>In elderly patients and in patients with mild to moderate renal dysfunction or mild to moderate hepatic impairment the pharmacokinetic behaviour of lercanidipine was shown to be similar to that observed in the general patient population; patients with severe renal dysfunction or dialysis- dependent patients showed higher levels (about 70%) of the drug. In patients with moderate to severe hepatic impairment, the systemic bioavailability of lercanidipine is likely to be increased since the drug is normally metabolised extensively in the liver.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity to reproduction.</p><p>Safety pharmacological studies in animals have shown no effects on the autonomic nervous system, the central nervous system or on gastrointestinal function at antihypertensive doses.</p><p>The relevant effects which have been observed in long-term studies in rats and dogs were related, directly or indirectly, to the known effects of high doses of Ca-antagonists, predominantly reflecting exaggerated pharmacodynamic activity.</p><p>Lercanidipine was not genotoxic and showed no evidence of carcinogenic hazard.</p><p>&nbsp;</p><p>Fertility and general reproductive performance in rats were unaffected by treatment with Lercanidipine.</p><p>&nbsp;</p><p>There was no evidence of any teratogenic effect in rats and rabbits; however, in rats, Lercanidipine at high dose levels induced pre- and post- implantation losses and delay in foetal development.</p><p>Lercanidipine hydrochloride, when administered at high dose (12 mg/kg/day) during labour, induced dystocia.</p><p>The distribution of Lercanidipine and/or its metabolites in pregnant animals and their excretion in breast milk have not been investigated.</p><p>Metabolites have not been evaluated separately in toxicity studies.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Lertiv 10 (Lercanidipine Hydrochloride Film-Coated Tablets 10mg):</strong></p><p>Lactose monohydrate; Cellulose, Microcrystalline, Sodium starch glycolate, Type -A (Primojel) (Part-I};Povidone, Cellulose, Microcrystalline, Sodium starch glycolate, Type -A,(Primojel) (Part-II) Magnesium stearate.</p><p>Film coating composition:</p><p>Polyvinyl alcohol-part Hydrolyzed; Titanium Dioxide ; Macrogol/Peg; Talc;;Iron Oxide Yellow Iron Oxide.</p><p>Lertiv 20 (Lercanidipine Hydrochloride Film-Coated Tablets 20mg):</p><p>Lactose monohydrate; Cellulose, Microcrystalline, Sodium starch glycolate, Type -A (Primojel) (Part-I};Povidone, Cellulose, Microcrystalline, Sodium starch glycolate, Type -A,(Primojel) (Part-II) Magnesium stearate.</p><p>Film coating composition:</p><p>Polyvinyl alcohol-part Hydrolyzed ; Titanium Dioxide; Macrogol/Peg; Talc; Iron Oxide Red.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&ordm;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>10&#39;s White opaque PVC/Aclar-Alu Blister pack</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not Applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Saudi Amarox Industrial Company,
Aljameah Street, Malaz quarter, Riyadh 11441 Saudi Arabia
Tel: +966 11 477 2215
Manufacture: Hetero Labs Unit V, Hyderabad, India

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                June-2023.
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>